|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
While cross talk between the Wnt/β-catenin and PI3K/AKT signaling pathways has been proposed, the impact of PI3K/AKT inhibition on β-catenin signaling in glioma remains unknown.
|
20888802 |
2010 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Western blot of p21, p27 and AKT indicated the possible role of TRIM44 in regulation AKT pathway in glioma.
|
31605296 |
2019 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We further demonstrated that activation of AKT is the driving force of GOLM1-promoted glioma progression.
|
29282077 |
2017 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found significant increases in T-cell expressions of PDK1, PI3K, and p-AKT in T11TS-treated animal groups compared to sharp downregulations in glioma.
|
28608562 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that miR-451 represses glioma in vitro and in vivo, likely through targeting CAB39 directly and inhibiting the PI3K/AKT pathway indirectly.
|
22179124 |
2012 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conclude that BAS-4 showed potential activity against glioma by inducing apoptosis mediated by ΔΨm loss and AKT pathway disruption, and future studies should further evaluate BAS-4 as a promising antineoplastic agent against glioblastoma.
|
30856536 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We also demonstrated that overexpression of miR-126 suppressed PI3K and AKT activation, which contribute to suppress tumor growth of glioma.
|
26617742 |
2015 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
VEGFR2 inhibitor SU-1498, AKT inhibitor LY294002 and FAK inhibitor 14 (FAK inhibitor) blocked the Robo4 knockdown-mediated alteration in glioma angiogenesis in vitro.
|
25833462 |
2015 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Together, these data indicate that IL-17 can promote the proliferation and migration of glioma cells via PI3K/Akt1/NF-κB-p65 activation, and these findings might provide a new insight into glioma pathogenesis.
|
30660646 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, the present study demonstrated that Src plays a biologically significant role in tumor proliferation and apoptosis and enhances the cytotoxic effect of temozolomide through AKT supression in glioma.
|
23338526 |
2013 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This RTK/PTEN/PI3K pathway leads to activated AKT and phospho-AKT levels are elevated in the majority of GBM tumor samples and cell lines, which studies show help glioma cells grow uncontrolled, evade apoptosis, and enhance tumor invasion.
|
21827416 |
2011 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results suggest that Liq treatment enhances glioma cell susceptibility to TMZ by inhibiting the PI3K/AKT/mTOR pathway.
|
25351348 |
2015 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
These results demonstrate that sevoflurane inhibits glioma cell migration and invasion and that these beneficial effects are mediated by the upregulation of miRNA‑637, which suppresses Akt1 expression and activity.
|
27840895 |
2016 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therapy based on AKT inhibition may complement currently available treatment to control glioma cell invasion.
|
15557754 |
2005 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The upregulation of miR‑342 inactivated the AKT and ERK pathways in glioma.
|
28677773 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The RAS/RAF mitogen-activated protein kinase pathway (MAPK) is highly active in many tumor types including the majority of high-grade gliomas and expression of activated RAS or RAF in neural progenitor cells combined with either AKT activation or Ink4a/Arf loss leads to the development of high-grade gliomas in vivo.
|
21057530 |
2011 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The newly identified miR-92a/KLF4/AKT/mTOR axis provides novel insight into the pathogenesis of glioma.
|
31378903 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
LHGDN |
The initial characterization of SH-6 included treatment of glioma cells with increasing doses of SH-6 (0.30-30 microM) and examining the effects on AKT signaling proteins by Western blot analyses and in kinase assays with immunoprecipitated AKT1.
|
17041888 |
2006 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The initial characterization of SH-6 included treatment of glioma cells with increasing doses of SH-6 (0.30-30 microM) and examining the effects on AKT signaling proteins by Western blot analyses and in kinase assays with immunoprecipitated AKT1.
|
17041888 |
2006 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of Akt1 protein and mRNA was similar in glioma and normal control tissues.
|
20167810 |
2010 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The current results also indicted that YKL-40 plays a pivotal role in glioma cell proliferation through activation of the MAPK and AKT pathways.
|
20499402 |
2010 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The circ-CFH/miR-149/AKT1 regulation axis may be a potential target for glioma therapy.
|
30111766 |
2018 |
|
Glioma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The serine/threonine-protein kinase PFTAIRE 1 (PFTK1) is a member of the cyclin‑dependent kinase family that is highly expressed in several malignant tumors, including hepatocellular carcinoma, esophageal, breast and gastric cancers, and glioma.
|
28498444 |
2017 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our results indicated that combined treatment of <sup>125</sup>I seeds and SAL achieved enhanced growth inhibition and apoptosis in human glioma in vitro and in vivo through triggering ROS-mediated DNA damage and regulation of MAPKs and AKT pathways, which validated that the combined strategy of using <sup>125</sup>I seeds and SAL could be a highly efficient way to achieve enhanced glioma chemo-radiotherapy.
|
29804240 |
2018 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our research indicated a MEG3-miR-93-PI3K-AKT pathway in regulating the growth of glioma, providing a promising therapy for glioma.
|
28791407 |
2017 |